

Protagen, Qiagen agreement, 2/15

February 2014—Protagen has entered into a long-term collaboration agreement with Qiagen to target the development of novel protein-based companion diagnostics for autoimmune disorders. Under the terms of the agreement, Qiagen will gain access to Protagen's proprietary SeroTag technology platform, which enables the discovery and validation of novel protein-based marker panels.

[Protagen](#), +49 231 9742 6300